This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kyowa Hakko Kirin Co., Ltd.
Drug Names(s): KW-6002, Nouriasuto, Istra phosphorus defi
Description: KW-6002 blocks adenosine A2A receptors, that are almost exclusively found on dopamine D2 receptor–bearing striatopallidal neurons. These neurons secrete the neurotransmitter GABA and have an inhibitory effect. It is thought that the reduction in dopamine seen in Parkinson's disease leads to overactivity in these neurons. KW-6002's blockade enhances the effects of dopamine on these neurons, thereby suppressing their inhibitory output.
Biovail and Kyowa Hakko Kirin
In June 2010, Biovail announced that its subsidiary, Biovail Laboratories International (BLS) acquired the U.S. and Canadian rights to commercialize products containing istradefylline. Under the terms of the agreement, BLS has paid an upfront fee of $10 million, and could pay up to $20 million in potential development milestones through U.S. Food and Drug Administration (FDA) approval and up to an additional $35 million if certain sales-based milestones are met. BLS will also make tiered, royalty payments of up to 30% on net commercial sales of products containing istradefylline. In connection with this transaction, BLS has also entered into a supply agreement with Kyowa Hakko Kirin for the supply of istradefylline.
Valeant and Biovail
Also in June 2010, Valeant and Biovail announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate...See full deal structure in Biomedtracker
Additional information available to subscribers only: